Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk
AbstractPurposeExisting high-risk clinic models focus on patients with known risk factors, potentially missing many high-risk patients. Here we describe our experience implementing universal risk assessment in an ambulatory breast center.MethodsSince May 2017, all breast center patients completed a customized intake survey addressing known breast cancer risk factors and lifestyle choices. Patient characteristics, family history, risk scores, and lifestyle factors were examined; patients with high-risk breast lesions were excluded. Patients were considered at increased risk by model thresholds Gail 5-year risk  > ...
Source: Breast Cancer Research and Treatment - January 21, 2019 Category: Cancer & Oncology Source Type: research

Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk?
ConclusionOur study is the first to provide follow-up information for males with ADH. With 6  years of mean follow-up, no male in our series has developed breast cancer. This suggests that either ADH in men does not pose the same risk as ADH in women or that surgical excision of symptomatic gynecomastia in men effectively reduces the risk of breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 21, 2019 Category: Cancer & Oncology Source Type: research

Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors
ConclusionsThese findings supplement existing evidence to inform treatment decisions that balance cancer control and cardiovascular toxic outcomes. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 18, 2019 Category: Cancer & Oncology Source Type: research

Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant
ConclusionsThe agreement of HER2 and Ki67 between CNB and paired surgical specimen in primary breast cancer is insufficient. Limited agreement of surrogate tumor subtypes indicates a significant clinical value of biomarker re-testing on surgical specimens. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 18, 2019 Category: Cancer & Oncology Source Type: research

Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials
ConclusionsBased on PFS and ORR results of this indirect meta-analysis, palbociclib, ribociclib, and abemaciclib are equally effective in either first- or second-line therapy for advanced ER  + BC. They, however, ported different toxicity profiles. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 18, 2019 Category: Cancer & Oncology Source Type: research

Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience
ConclusionsThis is the most extensive analysis of palbociclib in ≥ 4th-line setting. Clinical benefit was confirmed particularly for endocrine-sensitive, predominantly bony disease and in earlier lines of treatment. Safety was similar to PALOMA trials with higher febrile neutropenia rate. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 17, 2019 Category: Cancer & Oncology Source Type: research

BRCA1 / BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
AbstractPurposeBRCA1 and BRCA2 proteins are central to DNA repair process through homologous recombination. We hypothesize thatBRCA1/BRCA2 mutation carriers may exhibit increased hematological toxicity when receiving genotoxic chemotherapy.MethodsWe included women with primary breast cancers screened forBRCA1/BRCA2 germline mutations and treated with (neo)adjuvant chemotherapy in Geneva (Swiss cohort). The primary endpoint was the incidence of febrile neutropenia following the first chemotherapy cycle (C1). Secondary endpoints were the incidence of grade 3 –4 neutropenia, grade 4 neutropenia and hospitalization durin...
Source: Breast Cancer Research and Treatment - January 11, 2019 Category: Cancer & Oncology Source Type: research

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
AbstractPurposeIn the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23  months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) [hazard ratio (HR) 0.58;P 
Source: Breast Cancer Research and Treatment - January 10, 2019 Category: Cancer & Oncology Source Type: research

Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis
ConclusionsOur findings suggest a potential role for microenvironmental PDCs in breast cancer lymph node metastasis via CXCR4/SDF-1 axis. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 10, 2019 Category: Cancer & Oncology Source Type: research

Health-related quality of life of breast cancer patients in the Eastern Mediterranean region: a systematic review and meta-analysis
ConclusionsSince less than one-third of patients had a good QoL, it seems necessary to design and implement an integrated and multidimensional educational program to improve QoL of patients with breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 10, 2019 Category: Cancer & Oncology Source Type: research

PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review
ConclusionFurther investigation of PD-L1 expression in breast cancer and its effect on prognosis is required. There is little consensus on the methods used to evaluate PD-L1 expression immunohistochemically, and this may contribute to the diverging results found in this study. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 10, 2019 Category: Cancer & Oncology Source Type: research

Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
The article Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial, written by Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E. Kates, Michael Clemens, Wolfram Malter, Benno Nuding, Bahriye Aktas, Sherko Kuemmel, Toralf Reimer, Andrea Stefek, Fatemeh Lorenz-Salehi, Petra Krabisch, Marianne Just, Doris Augustin, Cornelia Liedtke, Calvin Chao, Steven Shak, Rachel Wuerstlein, Hans H. Kreipe, Nadia Harbeck, was originally published electronically on the publisher &rsq...
Source: Breast Cancer Research and Treatment - January 10, 2019 Category: Cancer & Oncology Source Type: research

National consensus recommendations on patient-centered care for ductal carcinoma in situ
ConclusionsThis is the first study to generate guidance on how to achieve PCC for DCIS. Organizations that deliver or oversee health care can use these recommendations on PCC for DCIS to plan, evaluate, or improve services. Ongoing research is needed to develop communication tools, and establish labels and language for DCIS that optimize communication. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 9, 2019 Category: Cancer & Oncology Source Type: research

Three-dimensional tumor visualization of invasive breast carcinomas using whole-mount serial section histopathology: implications for tumor size assessment
AbstractPurposeLinear tumor size (T-size) estimated with conventional histology informs breast cancer management. Previously we demonstrated significant differences in margin and focality estimates using conventional histology versus digital whole-mount serial sections (WMSS). Using WMSS we can measure T-size or volume. Here, we compare WMSS T-size with volume, and with T-size measured conventionally. We also compare the ellipsoid model for calculating tumor volume to direct, WMSS measurement.MethodsTwo pathologists contoured regions of invasive carcinoma and measured T-size from both WMSS and (simulated) conventional sect...
Source: Breast Cancer Research and Treatment - January 5, 2019 Category: Cancer & Oncology Source Type: research

Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers
ConclusionOur findings confirm the high annual rates of early-onset incident, contralateral and recurrent breast cancer among Polish BRCA1 mutation carriers. These risk estimates are important in the context of the clinical management of unaffected women as well as in the treatment of newly diagnosed primary breast cancers and can also be used as the basis for the planning of prevention trials. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 5, 2019 Category: Cancer & Oncology Source Type: research

Expression of Lamin A/C in early-stage breast cancer and its prognostic value
This study aimed to evaluate expression and prognostic significance of lamin A/C in early-stage breast cancer.MethodsUsing immunohistochemical staining of tissue microarrays, expression of lamin A/C was evaluated in a large well-characterised series of early-stage operable breast cancer (n = 938) obtained from Nottingham Primary Breast Carcinoma Series. Association of lamin A/C expression with clinicopathological parameters and outcome was evaluated.ResultsPositive expression rate of lamin A/C in breast cancer was 42.2% (n = 398). Reduced/loss of expression of lamin A/C was significantly associa...
Source: Breast Cancer Research and Treatment - January 4, 2019 Category: Cancer & Oncology Source Type: research

Clinical implications of germline mutations in breast cancer genes: RECQL
ConclusionsRECQL plays an important role in DNA repair, and is a plausible candidate breast cancer susceptibility gene. Initial studies showed evidence of an association between variants in this gene and an increased breast cancer risk in three separate populations, and identified founder mutations with significantly increased odds ratios. However, several subsequent studies have failed to support the association. With the limited and conflicting evidence available, there remains debate as to whether there is an increased breast cancer risk in individuals carryingRECQL loss of function variants. Further studies are require...
Source: Breast Cancer Research and Treatment - January 4, 2019 Category: Cancer & Oncology Source Type: research

Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior
AbstractBackgroundEpithelial-to-mesenchymal transition (EMT) has been implicated as an important step in the development of distant metastases. We therefore wished to study EMT status of primary breast carcinomas from patients who during follow-up developed distant metastases.MethodsmRNA expression profiles of primary breast carcinoma samples (n = 151) from patients who developed metastatic disease were analyzed and EMT status was designated using a previously described EMT-core signature. EMT status of the primary tumor was correlated to clinicopathological characteristics, molecular subtypes, metastasis pat...
Source: Breast Cancer Research and Treatment - January 4, 2019 Category: Cancer & Oncology Source Type: research

Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?
This study aims to evaluate whether extracapsular extension (ECE) in the sentinel lymph node (SLN) is associated with involvement of ≥ 4 lymph node metastases at completion axillary lymph node dissection (ALND) and the effect on 5-year disease-free survival (DFS) and 10-year overall survival (OS).Summary background dataECE in a SLN is usually a contraindication for omitting completion ALND in cT1-2N0 breast cancer patients treated with breast-conserving therapy and 1 –2 positive SLN(s).MethodsAll cT1-2N0 breast cancer patients with 1 –3 positive SLN(s) who underwent ALND between 2005 and 2008 were sel...
Source: Breast Cancer Research and Treatment - January 4, 2019 Category: Cancer & Oncology Source Type: research

Re: The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer. Breast Cancer Res Treat. Sep 2018;171(2):477-488
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 4, 2019 Category: Cancer & Oncology Source Type: research

Prevalence and characterization of ATM germline mutations in Chinese BRCA1 / 2 -negative breast cancer patients
AbstractPurposeThe ataxia telangiectasia-mutated (ATM) gene is a moderate susceptibility gene for breast cancer. However, little is known about the breast cancer phenotypes associated withATM mutation. We therefore investigated the spectrum and clinical characteristics ofATM germline mutations in Chinese breast cancer patients.MethodsA multi-gene panel was performed to screen forATM germline mutations in 7657BRCA1/2-negative breast cancer patients. All deleterious mutations were validated by independent polymerase chain reaction (PCR)-Sanger sequencing.ResultsA total of 31 pathogenic mutations in theATM gene across 30 carr...
Source: Breast Cancer Research and Treatment - January 3, 2019 Category: Cancer & Oncology Source Type: research

Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
ConclusionsDasatinib can be safely combined with trastuzumab and paclitaxel. The combination is active with an ORR of almost 80%.Trial registration: NCT01306942, EudraCT 2010-023304-27. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 3, 2019 Category: Cancer & Oncology Source Type: research

Comparison of treatment of early-stage breast cancer among Nurses ’ Health Study participants and other Medicare beneficiaries
ConclusionsNHS and the general female population had comparable treatment and utilization patterns following diagnosis of early-stage incident breast cancers with the exception of type of radiation therapy received. This study provides support for the larger value of population-based cohorts in research on healthcare costs and utilization in breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 3, 2019 Category: Cancer & Oncology Source Type: research

A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types
ConclusionsChk1 promotes an unexpected, common phenotype of chromatin-dependent DSB suppression in radioresistant TNBC and KRAS mutant cancer cells, providing a direction for future investigations into overcoming the treatment resistance of TNBC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 3, 2019 Category: Cancer & Oncology Source Type: research

Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer
ConclusionsWe revealed that palbociclib and MLN0128 had synergistic anti-cancer activity in both pRb  + ER-negative cell lines and a TNBC PDX model. Our results indicate that such combination therapy is worthy of further investigation in a clinical setting. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 3, 2019 Category: Cancer & Oncology Source Type: research

Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC
ConclusionsApproximately one-third of sporadic breast tumors show a high HRD score, indicating the presence of homologous recombination dysfunction, and they are characterized by biologically aggressive phenotypes, most commonly in the TNBC subtype, and less sensitive to P-FEC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 3, 2019 Category: Cancer & Oncology Source Type: research

Is microductectomy still necessary to diagnose breast cancer: a 10-year study on the effectiveness of duct excision and galactography
ConclusionsPatients with SND should continue to be evaluated with microductectomy to prevent missing a breast cancer. Moreover, we do not recommend performing galactography for diagnosing breast cancer due to poor sensitivity and specificity though it may assist in preoperative planning. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 3, 2019 Category: Cancer & Oncology Source Type: research

Peer support interventions for breast cancer patients: a systematic review
ConclusionsThis systematic review found that different types of peer support have different effects on outcomes for breast cancer patients. Web-based group peer support without peer training must be avoided or used with caution in the future. Peer education is recommended for breast cancer patient support models, given its excellent results and cost-effectiveness. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 2, 2019 Category: Cancer & Oncology Source Type: research

Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer
AbstractPurposePeripheral blood lymphopenia and elevated neutrophil-to-lymphocyte ratio (NLR) have been associated with poor outcomes in various malignancies. However, existing literature has largely focused on baseline parameters. The aim of this study is to assess the impact of radiation therapy (RT) and chemotherapy on absolute lymphocyte counts (ALC) and NLR in relation to survival outcomes in patients with triple-negative breast cancer (TNBC).MethodsA retrospective analysis was performed on 126 patients with TNBC treated at Washington University between 2005 and 2010. Cox proportional hazard model with time-varying co...
Source: Breast Cancer Research and Treatment - January 2, 2019 Category: Cancer & Oncology Source Type: research

Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case –control study
ConclusionsIn this first investigation of folic acid supplement use and breast cancer risk inBRCA mutation carriers, these findings suggest that moderate folic acid- and vitamin B12-containing supplement use may be protective forBRCA-associated breast cancer, particularly amongBRCA1 mutation carriers. Future studies with larger samples and prospective follow-up are needed. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 2, 2019 Category: Cancer & Oncology Source Type: research

An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer
ConclusionAlthough each of the articles contributed their own analytic strengths and limitations, the overall quality of the studies was moderate. The review demonstrated that the vast majority of the reported incremental cost-effectiveness ratios exceeded the typically employed willingness to pay thresholds used in each country of analysis. Only three of the reviewed articles studied chemotherapies rather than treatments targeting either HER2 or hormone receptors, demonstrating a gap in the literature. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 2, 2019 Category: Cancer & Oncology Source Type: research

Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer
ConclusionsThis analysis shows an association between HRT and the distribution of molecular subtypes of BC. However, no associations between other factors (e.g., age at diagnosis, body mass index, smoking status, age at menopause, number of deliveries, age at first delivery, breastfeeding history, or family history) were noted. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 2, 2019 Category: Cancer & Oncology Source Type: research

Pre-diagnostic sex hormone levels and survival among breast cancer patients
ConclusionsPre-diagnostic postmenopausal circulating estradiol levels were modestly associated with worse survival among breast cancer patients. Further studies should evaluate whether circulating hormone levels at diagnosis predict cancer prognosis or treatment response. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 2, 2019 Category: Cancer & Oncology Source Type: research

The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis
ConclusionsRoutine baseline cardiac assessments prior to AA in all EBC patients have low yield and infrequently affect clinical management. Future studies should further examine potential predictors of abnormal cardiac functions in an attempt to identify low risk patients in whom routine baseline LVEF assessment may not be warranted and prevent delay in chemotherapy administration. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 2, 2019 Category: Cancer & Oncology Source Type: research

Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer
ConclusionOur results support the conclusions published by Cardoso et al. by providing additional evidence that the 70-gene signature can be used to avoid overtreatment by CT for women with high clinical risk but low genomic risk. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 2, 2019 Category: Cancer & Oncology Source Type: research

Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence
ConclusionsASCs migrate toward chemo-residual TNBC cells via SDF-1 α/CXCR4 signaling, and drive chemo-residual tumor cell proliferation in a paracrine manner by secreting FGF2 and activating ERK. This paracrine signaling can potentially be targeted to prevent tumor recurrence. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 29, 2018 Category: Cancer & Oncology Source Type: research

The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women ’s characteristics: is it the same?
This study included 3,609,569 screening mammograms performed from 2002 to 2015 in our organized breast cancer screening program, which actively invites women 50 –69 years of age. The association between women’s characteristics and the DCIS detection rate, the IBC detection rate and the odds ratio of DCIS among screen-detected cancers was assessed by logistic regression and generalized estimating equations with independent correlation matrix and sandwic h estimator.ResultsA total of 4173 DCIS and 15,136 IBC were screen-detected. Increasing women ’s age, current hormone replacement therapy use and high...
Source: Breast Cancer Research and Treatment - December 18, 2018 Category: Cancer & Oncology Source Type: research

The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies
ConclusionsThis study suggests that the ER S118P variant does not affect risk for breast cancer or hormone therapy resistance. Germline screening and modification of treatments for patients harboring this variant are likely not warranted. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 17, 2018 Category: Cancer & Oncology Source Type: research

Prevalence of breast cancer-related risk factors in underweight premenopausal women: the Korea National Health and Nutrition Examination Survey IV –VI
This study aimed to examine the prevalence and trends of breast cancer-related risk factors and characteristics in premenopausal underweight Korean women according to birth year cohort.MethodsSocioeconomic and breast cancer-related risk factors were investigated in 13,415 premenopausal women using nationwide cross-sectional surveys performed between 2007 and 2015. Underweight was defined as body mass index  
Source: Breast Cancer Research and Treatment - December 17, 2018 Category: Cancer & Oncology Source Type: research

Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990 –2011
ConclusionrMBC incidence declined over time with decreased HER2-positive distant recurrence, a shift to more triple-negative BC and consistently poor distant disease survival. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 17, 2018 Category: Cancer & Oncology Source Type: research

Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer
AbstractPurposeCD133/ prominin 1 is a cancer stem cell marker associated with cancer progression and patient outcome in a variety of solid tumours, but its role in invasive breast cancer (BC) remains obscure. The current study aims to assess the prognostic value of CD133 expression in early invasive BC.MethodsCD133 mRNA was assessed in the METABRIC cohort and at the proteomic level using immunohistochemistry utilising a large well-characterised BC cohort. Association with clinicopathological characteristics, expression of other stem cell markers and patient outcome were evaluated.ResultsHigh expression of CD133 either in m...
Source: Breast Cancer Research and Treatment - December 15, 2018 Category: Cancer & Oncology Source Type: research

Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G & gt;T
ConclusionsOur results support a pathogenic classification forPALB2 c.3201+5G>T, highlighting the impact of variants causing an imbalanced expression of natural RNA isoforms in cancer susceptibility. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 14, 2018 Category: Cancer & Oncology Source Type: research

Diagnostic pathways and management in women with pregnancy-associated breast cancer (PABC): no evidence of treatment delays following a first healthcare contact
ConclusionsThese findings do not support the notion that diagnostic and treatment delays following a first healthcare contact are more common in women diagnosed with breast cancer during or shortly after pregnancy. However, there was some evidence of delays in seeking healthcare among pregnant and lactating women. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 14, 2018 Category: Cancer & Oncology Source Type: research

Ectopic breast tissue and cancer
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 13, 2018 Category: Cancer & Oncology Source Type: research

Clinical findings and outcomes of MRI staging of breast cancer in a diverse population
AbstractBackgroundThe performance of magnetic resonance imaging (MRI), the effect of patient factors, and resulting surgical management in underserved and ethnically diverse breast cancer (BC) patient populations have been understudied.MethodsWe retrospectively analyzed the data of 1116 consecutive patients who were newly diagnosed with in situ or invasive BC with preoperative staging MRI. Non-index lesions (NILs) were defined as abnormal MRI findings with BI-RADS score of 4 or 5 in breast or axillary nodes not previously detected by conventional imaging. Occult cancers (OCs) were NILs found to be malignant by biopsy or su...
Source: Breast Cancer Research and Treatment - December 12, 2018 Category: Cancer & Oncology Source Type: research

Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands
ConclusionIn this cohort of 4901 patients, we observed substantial inter- and intra-laboratory variation in DCIS grading, not explained by differences in case-mix. Therefore, there is an urgent need for nationwide standardization of grading practices, especially since the future management of DCIS may alter significantly depending on histologic grade. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 11, 2018 Category: Cancer & Oncology Source Type: research

KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients
AbstractAimTo investigate the clinical and prognostic significance of circulated tumor cells (CTC) marked by cytokeratin 19 coding geneKRT19 mRNA and carcinoembryonic antigen coding geneCEACAM5 mRNA in preoperative peripheral blood of breast cancer patients and provide molecular markers for breast cancer metastasis risk.MethodsThe mRNA levels ofKRT19 andCEACAM5 in preoperative peripheral blood of breast cancer patients without (n = 603) and with (n = 76) distant metastases at the time of initial diagnosis were detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Th...
Source: Breast Cancer Research and Treatment - December 8, 2018 Category: Cancer & Oncology Source Type: research

Leveraging the variable natural history of ductal carcinoma in situ (DCIS) to select optimal therapy
ConclusionA clearer understanding of the variable history of DCIS coupled with advances in genomic profiling of the disease holds the promise of reducing widespread over-treatment of this non-invasive cancer. Additionally, identification of higher risk of recurrence subsets may select patients for whom more aggressive treatment may be appropriate. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 8, 2018 Category: Cancer & Oncology Source Type: research

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial
AbstractPurposeTo investigate the efficacy of metformin (M) plus chemotherapy versus chemotherapy alone in metastatic breast cancer (MBC).MethodsNon-diabetic women with HER2-negative MBC were randomized to receive non-pegylated liposomal doxorubicin (NPLD) 60  mg/m2 + cyclophosphamide (C) 600 mg/m2 × 8 cycles Q21 days plus M 2000 mg/day (arm A) versus NPLD/C (arm B). The primary endpoint was progression-free survival (PFS).ResultsOne-hundred-twenty-two patients were evaluable for PFS. At a median follow-up of 39.6 months (interquartile range [IQR] 24.6 –50.7 months), 112 P...
Source: Breast Cancer Research and Treatment - December 7, 2018 Category: Cancer & Oncology Source Type: research

Identifying adherence barriers to oral endocrine therapy among breast cancer survivors
ConclusionThe determinants of non-adherence and non-persistence are multi-dimensional and influenced by several factors. The three categories of adherence barriers should be evaluated and considered when designing future interventions to enhance OET adherence for a tailored approach. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 6, 2018 Category: Cancer & Oncology Source Type: research